BriaCell is developing personalized peptide-and-cell immunotherapy for metastatic cancer, with two programs anchoring the pipeline. Bria-IMT — a whole-cell allogeneic immunotherapy — is in Phase 3 in advanced metastatic breast cancer, with positive quality-of-life and biomarker data presented at AACR 2026 and six accepted abstracts at ASCO 2026 covering 12- and 24-month survival, treatment tolerability, and circulating-tumor-cell biomarker work. The next-generation Bria-OTS+ platform pairs HLA-matched cells with peptide-mediated antigen targeting; preclinical anti-cancer data presented at AACR 2026 (April 21) supports planned clinical entry for metastatic breast and prostate cancer late 2026, with lung and melanoma indications targeted for 2027.
The Phase 3 patient-enrollment update remains on track for 1H 2026 topline data, and the Bria-ABC randomized Phase 3 also features a blood-biomarker progression-free-survival readout. Stories here cover trial readouts, AACR and ASCO presentations, and the broader peptide-immunotherapy field. See #bria-imt, #peptide-vaccine, and #metastatic-breast-cancer.
BriaCell announced April 21 preclinical results from its next-generation Bria-OTS+ personalized peptide immunotherapy at the AACR 2026 Annual Meeting. The platform pairs HLA-matched whole-cell allogeneic immunotherapy with peptide-mediated antigen targeting, building on the Bria-IMT clinical foundation in heavily pretreated metastatic breast cancer. Based on the preclinical anti-cancer activity, BriaCell plans to enter the clinic for metastatic breast cancer and prostate cancer indications later in 2026, with lung cancer and melanoma planned for 2027. The program adds to a peptide-immuno-oncology pipeline that includes the Bria-IMT Phase 3 and the company's six accepted ASCO 2026 presentations covering survival data, biomarkers, and quality-of-life endpoints.
BriaCell announced April 27 that its Bria-IMT cell-based peptide immunotherapy will be featured in three poster presentations and three publication-only abstracts at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago). Highlights include 12- and 24-month overall survival data with Bria-IMT plus checkpoint inhibition in advanced metastatic breast cancer, an updated quality-of-life and tolerability analysis, and a randomized Bria-ABC Phase 3 blood-biomarker progression-free survival readout. Three publication-only abstracts cover the second-generation BC1 platform, multi-analyte liquid biopsy stratification, and PD-L1 monitoring in circulating cancer-associated cells.
BriaCell's Bria-IMT + checkpoint inhibitor combination preserved overall health status and key functional quality-of-life measures in its pivotal Phase 3 study in heavily pretreated metastatic breast cancer patients who had failed ADC, CPI, and CDK4/6 inhibitor therapy. Phase 2 biomarker analyses identified mitotic circulating tumor cells as prognostic and PD-L1 in tumor-macrophage fusion cells as predictive of checkpoint benefit. Presented at AACR April 20.